The chemokine CCL11 has been implicated in age-related cognitive deterioration in mice, yet evidence on the relationship between CCL11 and cognitive function in humans is limited. This study explored associations between CCL11 and cognition in rural and urban community-dwelling older adults. Participants were 515 urban dwellers from the 3C-Bordeaux cohort and 318 rural dwellers from the AMI cohort. Plasma CCL11 was measured using an enzyme-linked immunoassay. Mini Mental State Examination (MMSE) test scores were used as the main measure of cognitive performance. Multivariate regression analysis was used to evaluate the cross-sectional association between CCL11 and cognitive performance. CCL11 was significantly higher in rural dwellers compared to city dwellers (median pg/mL vs. 103 pg/mL; p < 0.001). After adjustment for confounders, CCL11 was found to be negatively associated with cognitive performance in rural dwellers but not in city dwellers. These results suggest that CCL11 may be an independent determinant of cognitive function in older rural dwellers and that the residential environment modifies this association.
Introduction
Chronic systemic inflammation is increasingly recognized as a contributing factor in the etiology of age-related cognitive decline and neurodegenerative diseases (Bourassa and Sbarra, 2017; Sankowski et al., 2015; Weaver et al., 2002) . However, epidemiological studies exploring relationships between markers of inflammation and cognitive function have produced mixed and often inconsistent results (Bettcher and Kramer, 2014; Sharma et al., 2016) . In this context, among a number of putative circulating inflammatory mediators, the chemokine C-C motif ligand 11 (CCL11), also known as eotaxin-1, has recently emerged as a potential pathophysiologically relevant age-related negative regulator of neurogenesis and cognitive function in mice (Villeda et al., 2011) . Widely recognized as an eosinophil chemoattractant, CCL11 plays an important role in the pathogenesis of allergic conditions such as asthma and in inflammatory diseases of the gastrointestinal tract (Williams, 2015) . More recently, circulating levels of CCL11 have been shown to rise with normal human ageing (Bradburn et al., 2018; Shurin et al., 2007; Villeda et al., 2011) and in neurodegenerative diseases (Huber et al., 2018) . In particular, small studies have linked higher blood levels of CCL11 with Alzheimer's disease (AD) (Choi et al., 2008) and with memory deficits in older adults diagnosed with mild cognitive impairment (MCI) and AD dementia phenotypes (Bettcher et al., 2016) . In contrast, high CCL11 levels were found to correlate with a delayed age at onset in AD (Lalli et al., 2015) suggesting a complex role of this chemokine in neurodegeneration.
Little is known about the relationship between CCL11 and cognitive function in healthy older humans, particularly in the context of varying socio-demographic factors. Population-based studies indicate that cognitive performance in older adults is influenced by socio-demographic characteristics, with level of education, gender, age and income showing consistent associations (Wight et al., 2006) . Few studies have also examined the influence of the residential environment (rural or urban) on cognition but the findings have been inconsistent (Crowe et al., 2010; Nunes et al., 2010; Saenz et al., 2018; Xu et al., 2017) . Elucidating how the residential context impacts on the biological https://doi.org/10.1016/j.exger.2018.10.004 Received 28 August 2018; Received in revised form 28 September 2018; Accepted 4 October 2018 processes associated with cognitive decline may help to better understand the pathophysiological mechanisms underlying this condition. Therefore, in this study we examined if circulating levels of plasma CCL11 are associated with cognitive performance in older adults living in the community and if the relationship would differ between rural and urban dwellers.
Methods

Study population
Participants in this cross-sectional study were men and women aged 65 and older from two well characterised population-based French cohorts, namely, Three-City (3C) (The 3C Study Group, 2003) and Approche Multidisciplinaire Intégrée (AMI) (Peres et al., 2012) , who were enrolled in 2013 to the exploratory phase of the FRAILOMIC initiative, a European project investigating biomarkers of frailty (Erusalimsky et al., 2016) . The 3C is a population-based prospective cohort formed during 1999-2000 to study the vascular risk factors of dementia in non-institutionalized city dwellers randomly selected from the electoral roles of three urban areas, namely Dijon, Montpellier and Bordeaux (The 3C Study Group, 2003) . Only participants from the Bordeaux 10-year-follow-up wave (n = 1214), for whom a comprehensive set of parameters were recorded, were considered for enrolment to FRAILOMIC. The AMI is a population-based prospective cohort (n = 1002) started in 2007 to study health and ageing in elderly farmers living in rural South West France, which were selected randomly from the database of the French Farmer Health Insurance System (Peres et al., 2012) . All participants gave written informed consent and the study was approved by the Ethics committees of the participating institutions: the 3C study protocol was approved by the Consultative Committee for the Protection of Persons participating in Biomedical Research at Kremlin-Bicêtre University Hospital (Paris) and the AMI study was approved by the Ethics Committee of the CHU (University Hospital) of Bordeaux. The research followed the principles embodied in the Declaration of Helsinki.
Participants from the two cohorts were recruited and investigated following similar procedures, therefore allowing for comparative analyses. In both cohorts, a wide range of data was collected by a neuropsychologist during a home visit, including anthropometric measurements, frailty assessment, neuropsychological testing and recording of sociodemographic characteristics, lifestyle habits, medication and medical history. Blood sampling was also conducted in both cohorts. Individuals were eligible for inclusion in FRAILOMIC if a blood specimen was available for biomarker evaluation and if the frailty status could be determined using the frailty criteria proposed by Fried et al. (Fried et al., 2001) . A total of 525 subjects from 3C-Bordeaux fulfilled the aforementioned selection criteria. In AMI, among 695 participants with available blood specimens, all subjects diagnosed as frail (n = 80) were included in the study, whereas selection of the non-frail participants was constrained to achieve a ratio of 1 case to 3 controls and a similar cardiovascular risk profile in both groups. This led to a total AMI subset of 320 subjects. Using 25 variables including socio-demographic and clinical data, disability and death, an inverse probability weighting was applied to the AMI subset in order to limit the selection bias which had led to an over-representation of the frail subjects in this group.
Cognitive tests
At the time of the FRAILOMIC sampling, three cognitive tests had been administered in both cohorts, namely the Mini-mental State Examination (MMSE), the Free and Cued Selective Reminding Test RL/ RI-16 items (FCSRT) and the Isaacs Set Test (IST). The MMSE test was considered as the main outcome since it is a questionnaire assessing global cognitive performance. The MMSE score ranges from 0 to 30, with a higher score indicating better performance (Folstein et al., 1975) . The FCRST is used to assess episodic memory with a score ranging from 0 to 48, also increasing with the level of cognitive performance (Grober et al., 1988) . Finally, the IST is a verbal fluency assessment test that requires subjects to recall items in four different semantic categories (fruits, animals, colours and cities). This test was limited to 15 s in the present analysis, with a maximum score of 10 words per category and consequently a maximum total score of 40 (Isaacs and Akhtar, 1972) .
Measurement of CCL11
Plasma levels of CCL11 were determined from fasting blood samples stored at −80°C using a commercially available sandwich ELISA (Quantikine Human CCL11/Eotaxin Immunoassay, R&D Systems, Abingdon, UK). The intra-and inter-assay coefficients of variation were 1.2% and 3.1%, respectively.
Other variables
Sociodemographic information recorded at baseline included age, gender, monthly income and level of education, which in the present analysis was subdivided into three categories: low (Primary School or less, ages 3-11), intermediate (Secondary School, cycles 1 and 2, ages 12-18) and high (University, age > 18). Body Mass Index (BMI) was calculated as weight in kilograms divided by height in meters squared. Frailty was evaluated using Fried's criteria (Fried et al., 2001 ). The degree of disability was assessed using a hierarchical index which distinguishes four levels: no disability, mild, moderate and severe disability (Barberger-Gateau et al., 2000) . Depressive symptoms were assessed using the Center for Epidemiologic Studies-Depression scale (CES-D, 20-item version). A score ≥17 for men and ≥23 for women was considered as an indicator of a clinically relevant depression (Fuhrer and Rouillon, 1989 ). Medication use was categorised as taking < 5 drugs, 5-9 drugs or > 9 drugs.
Statistical analysis
Comparison of sociodemographic characteristics and health indicators
Continuous variables are reported as means ± SD for normally distributed data or as medians with IQR for skewed data. Categorical variables are presented as percentages. Differences in characteristics between groups were compared by χ 2 test or by Fisher's exact test for categorical variables, and by Student's t-test or Mann-Whitney test for continuous variables, as appropriate. Missing data (around 17% of the total database) were imputed by multiple regression imputation (Seaman et al., 2012) .
Regression analyses
The association between CCL11 and cognition was evaluated by linear regression analysis when the results of the cognitive tests were considered in their continuous form. In addition, for the two cognitive tests for which a clinically relevant threshold was available (i.e. MMSE and FCSRT), and hence scores could be dichotomised, logistic regression models were applied. For the MMSE test we used the square root of the error number to respect the Gaussian distribution (Jacqmin-Gadda et al., 1997) and a score of 24/30 as the clinically relevant threshold (Tombaugh and McIntyre, 1992) . For the FCSRT a threshold of 17/48 was used (Auriacombe et al., 2010) . Analyses were initially performed on the pooled data subsets. Models were adjusted for age, gender, level of education and living environment (cohort). Due to the cohort effect (see Results section), further analyses were carried out separately on each cohort subset. Given the skewed distribution of CCL11, for its evaluation as a continuous variable it was natural log-transformed (ln CCL11) before further analysis. Analyses were performed using Statistical Analysis System (SAS) version 9.4® (SAS Institute, Inc., Cary, NC, USA). Fig. 1 shows a flow chart depicting the selection of participants from the 3C and AMI cohorts enrolled in FRAILOMIC and their progression through the current study. A total of 517 participants from 3C-Bordeaux and 320 participants from AMI had sufficient blood available to have their plasma CCL11 determined. Of these, two participants in each subset was excluded from the analysis for giving an out of range CCL11 concentration (i.e. > 700 pg/mL). The characteristics of the participants from the two cohort subsets are presented in Table 1 . In addition to the living environment, the two subsets showed significant differences in the majority of the studied characteristics. Thus, compared with participants from 3C, AMI participants were significantly younger, with the majority being male, having a lower income and lower levels of education. Furthermore, significant differences in the clinical characteristics were also observed, with AMI participants showing a higher average BMI and a lower prevalence of disabilities or depression. In addition, the AMI participants showed poorer cognitive performances than those of 3C on all tests used. For example, the mean MMSE score of the AMI subset was 24.9 compared to 27.6 in the 3C subset, with 27% of AMI participants scoring below the threshold of 24 compared to only 6.7% in the 3C subset. Finally, median CCL11 concentrations were significantly higher in AMI compared to 3C (145.1 pg/mL vs 103.3 pg/ mL, respectively).
Results
Characteristics of the participants
Relationship between CCL11 levels and cognitive performance
In order to explore the relationship between CCL11 levels and cognitive performance, multivariate regression analyses were performed on the pooled cohort subsets (Table 2) . After adjusting for age, gender and level of education (model 2) the odds of exhibiting global cognitive impairment (i.e. MMSE score < 24) increased more than two-fold per unit increment of ln CCL11 (OR = 2.40, 95% CI 1.43;4.02, p < 0.001). Results remained significant when the MMSE score was considered as a continuous variable (β = 0.29, 95% CI 0.15;0.44, p < 0.001). However, after further adjustment for the living Fig. 1 . Flow chart of the study sample selection. The criteria used for the selection of participants is described in the main text. environment (rural/urban) these associations were no longer significant (Table 2, (Table 2 , model 3). Given the considerable difference in CCL11 concentrations between the two cohort subsets (Table 1) , and the effect of the living environment (Table 2 , model 3), further analyses were conducted on the two cohort subsets separately (Table 3 ). In the AMI cohort significant associations persisted between ln CCL11 and MMSE scores (OR = 2.23, 95% CI 1.92;2.58, p < 0.001 and β = 0.22, 95% CI 0.14;0.29, p < 0.001). Similarly, in this cohort an increase in ln CCL11 was associated with greater odds of scoring poorly for episodic memory, i.e. FCSRT score < 17/48 (OR = 1.33, 95% CI 1.13;1.56, p = 0.001), except that in this case the relationship was lost when the FCSRT score was considered as a continuous variable. In contrast, no relationship was observed for verbal fluency in the AMI cohort. None of the cognitive tests scores investigated as continuous or dichotomic variables were significantly associated with CCL11 levels in the 3C cohort (Table 3) .
Secondary analysis
To our knowledge there is no clinically relevant threshold for the categorization of CCL11 concentrations. In the absence of such a threshold, the distribution of CCL11 concentrations measured in the AMI cohort subset was divided by tertiles in order to assess the extent to which increasing cutoff values could distinguish participants who displayed greater odds of performing poorly in the cognitive tests. As shown in Table 4 , for the MMSE test the odds of exhibiting lower cognitive performance (i.e. MMSE score < 24) increased almost 1.6 fold for participants in the intermediate tertile of CCL11 (124.72-177.44 pg/mL) and almost 2.8 fold for those falling in the highest tertile (p < 0.001 vs. the lowest tertile). Results also remained significant when the MMSE score was considered as a continuous variable. Similarly, participants falling in the higher ranges of CCL11 exhibited higher odds of performing poorly in the FCSRT. In contrast this analysis did not show significant associations with IST scores (Table 4) .
Discussion
The present study provides evidence relating plasma levels of the chemokine CCL11 with cognitive performance in community-dwelling older adults from South Western France. Specifically, it shows that in a cohort of rural dwellers increased CCL11 is associated with poorer cognitive performance independently of relevant covariates. Importantly, this study did not find such a relationship in a cohort of city dwellers from the same region of France, despite the fact that both population samples were tested following the same procedures. Thus, our study suggests that the living environment influences the association between CCL11 and cognitive performance. To our knowledge, no significant association between CCL11 and cognition had been previously reported in elderly population samples of the types involved in this study.
The association between CCL11 and cognitive performance was clearly demonstrated when assessing global cognitive function (MMSE test) and to a lesser extent when evaluating episodic memory (FCSRT); the latter was manifested only when the results of the FCSRT were dichotomised. Noticeably, no relationship was observed between CCL11 and verbal fluency as measured by the IST. Both the FCSRT and the IST measure more narrow aspects of cognitive function, namely, memory and recall, respectively. Thus, it is possible that the association with CCL11 levels is more robustly manifested when assessing global cognition.
The relationship between measures of cognition and CCL11 has not been widely explored. Small studies in patients diagnosed with MCI or AD have generated mixed findings (Bettcher et al., 2016; Leung et al., 2013; Westin et al., 2012) . Bettcher et al. found that higher levels of CCL11 in combination with MCP-1 predict worse memory functions in MCI and AD phenotypes (Bettcher et al., 2016) , whereas Leung and coworkers reported significantly higher levels of CCL11 in patients with AD compared to those with MCI (Leung et al., 2013) . However, in sharp contrast, another study found that levels of CCL11 were reduced in patients with MCI who developed AD within 4-7 years compared to those who remained stable during the same period (Westin et al., 2012) . In addition, a study by Bradburn et al. showed that CCL11 was negatively associated with episodic memory and global cognition scores in relatively healthy elderly adults. However, this association was lost after adjusting for confounders (Bradburn et al., 2018) . Thus, so far the evidence relating blood CCL11 with cognitive function in humans is limited and inconclusive. In our study, it was striking that CCL11 levels were associated with cognitive performance in rural dwellers but not in city dwellers. One possibility to explain this difference is that CCL11 would be detrimental to cognitive function only if it was elevated above a pathophysiologically relevant threshold. In support of this possibility we found that (i) the median CCL11 was~50% higher in the AMI subset compared to the 3C subset, and (ii) AMI participants in the middle and upper tertiles of CCL11 had greater odds of exhibiting lower cognitive performance scores (as measured by the MMSE test and the FCSRT) than those in the lowest tertile.
The reason as to why rural dwellers exhibited higher levels of CCL11 compared to city dwellers is not known. Importantly, CCL11 determinations for both cohorts were undertaken in the same laboratory, at the same time and with the origin of the samples blinded to the operator. Although the AMI subset had a much larger proportion of males than the 3C subset, CCL11 levels in plasma are not influenced by gender (Hoefer et al., 2017; Larsson et al., 2015) . In contrast, CCL11 has been reported to be higher in older individuals (Bradburn et al., 2018; Shurin et al., 2007; Villeda et al., 2011) . However, participants included in the AMI subset were on average 6.2 years younger than those in the 3C subset (Table 1) . Therefore, gender or chronological age cannot account for the difference in CCL11 seen between the two cohort subsets. Levels of this chemokine are known to be raised by exposure to chemical, food and air-borne allergens (Matsuura et al., 2009; Meller et al., 2007; Minshall et al., 1997) . Whether rural dwellers were subjected to higher and/or more persistent levels of exposure to such substances than their city counterparts remains to be established. If that were to be the case and considering that long term exposures to inflammatory environments negatively affect cognitive status (Baldi et al., 2011; Marshall et al., 2000) , we hypothesize that this association might be in part mediated by CCL11. Thus, the current findings could expand our understanding of how the environment influences the pathophysiological processes underlying cognitive decline.
The precise biological mechanisms through which plasma CCL11 might be related to cognitive performance are yet to be delineated. CCL11 is able to cross the blood brain barrier and hence it is possible that systemic elevation of this chemokine will affect brain functions (Erickson et al., 2014) . Consistent with this possibility there is evidence to suggest that adverse changes in brain morphology may mediate the association of peripheral inflammation with cognitive performance (Marsland et al., 2015) . Indeed, studies in mice show that CCL11 impairs hippocampal neurogenesis and learning and memory (Villeda et al., 2011) . In addition, in vitro studies have demonstrated that CCL11 induces microglial cells to produce reactive oxygen species, promoting excitotoxic neuronal death (Parajuli et al., 2015) . Thus, CCL11 might cause neuronal damage and impair cognitive functions independent of eosinophil recruitment.
The present study has important strengths, including that it was carried out in well-characterised cohorts and with relatively large sample sizes. Nonetheless, it also has several limitations. First, although AMI and 3C are longitudinal cohorts, the present analysis is cross-sectional so a causal conclusion cannot be drawn as to whether increased plasma CCL11 contributes towards the deterioration of cognitive function or if it is simply a marker of another biological process that affects cognition. Second, although we controlled for age, gender and level of education, other non-recorded variables could be affecting the association, for example, vitamin D levels (Kubeczko et al., 2016) . Third, when considering the applicability of the results from this study to other populations it should be born in mind that ethnicity and socioeconomic position are generally known to impact on cytokine/chemokine profiles. In the particular case of CCL11, there is evidence of ethnic variation in its circulating concentrations, with individuals of African ancestry having lower levels than those of Eurasian Ancestry (Castillo et al., 2010; Coussens et al., 2013 ). In the current study rural dwellers were mostly Caucasians from the same region of France and of a mixed socioeconomic background, albeit with a higher proportion being on lower incomes. Hence, the present findings might not generalize to other rural communities with different ethnic and/or socioeconomic composition. A final limitation of our study is its inability to establish if the observed relationship between cognitive status and CCL11 is part of a more generalised heightened inflammatory state, since we had no further biological data on the inflammatory status of the participants.
Conclusions
In summary, despite the above-mentioned limitations, our study adds to the growing literature relating drivers of inflammation to cognitive decline, and might have implications for understanding the biological pathways through which social and environmental factors influence cognition. We report for the first time that in older individuals living in a rural environment, and otherwise free from clinically diagnosed neurodegenerative diseases, increased levels of CCL11 are associated with a lower cognitive performance. Longitudinal studies are needed to establish the causal relationships between this chemokine and cognitive function and if it can be used as a biomarker to predict cognitive decline.
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